Breast Cancer – EA1131 – Triple Negative
Sponsor: Easton Cooperative Group (ECOG)
Phase III
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Eligibility Criteria for Screening and Molecular Profiling (Step 0)
- Age ≥ 18 years
- Confirmed triple negative invasive breast cancer ER-, PR- HER2- (stage II or III)
- Completed definitive surgery of primary tumor with residual invasive cancer at time of surgery
- Radiotherapy may be given before or after protocol treatment
- Must have completed neoadjuvant taxane ± anthracycline–based chemotherapy
Exclusion Criteria:
- Cannot have received cisplatin, carboplatin, or capecitabine in the neoadjuvant setting
To learn more about available clinical research trials contact:
Deborah Brunetti, RN, CRC
Hunterdon Regional Cancer Center – Research Department
2100 Wescott Drive
Flemington, NJ 08822
908-237-2330 option #3